Latex allergy: the perspective from the surgical suite.
Latex allergy in the perioperative setting presents unique challenges to the health care system. Specific needs of the latex-sensitive patient are paramount, but consideration must also include the impact on health care workers vis-a-vis latex sensitization, environmental allergen control, and barrier protection against blood-borne pathogens. It has been well documented that the greatest source of latex aeroallergen in the surgical setting is latex gloves (both sterile and nonsterile). Levels of latex aeroallergen correlate strongly with use of high-allergen and powdered gloves, total number of gloves used, and the hours of activity in a given environment. A significant reduction in aeroallergen (>10-fold) can be achieved by switching to low-allergen gloves. Ready availability of and encouragement to use nonlatex alternatives when appropriate can further reduce exposure to latex allergens. Since 1998, the Food and Drug Administration has required all medical devices (or their packaging) that contain natural rubber latex to be so labeled. In addition, industry has responded with a host of latex-free products for use in patient care. This has helped eliminate a great deal of confusion about which products are safe for use with latex-sensitive individuals. However, despite significant efforts to educate the public and the health care industry regarding latex allergies, considerable misinformation persists. Provision of a completely latex-free environment in most surgical suites may be unrealistic, but every effort should be made to minimize the unnecessary exposure of patients and health care workers to latex allergens in this high-risk arena.
Elliott
Beth A
BA
Department of Anesthesiology, Mayo Medical School, Mayo Clinic, Rochester, Minnesota 55905, USA.
D000485:Allergens / Q000276:immunology; D004781:Environmental Exposure; D013502:General Surgery; D005932:Gloves, Surgical / Q000009:adverse effects; D006801:Humans; D006969:Hypersensitivity, Immediate / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*; D007073:Immunoglobulin E / Q000276:immunology; D007840:Latex / Q000009:adverse effects; D020315:Latex Hypersensitivity / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*; D015995:Prevalence; D012308:Risk Management; D012408:Rubber / Q000009:adverse effects
D000485:Allergens; D007840:Latex; D007073:Immunoglobulin E; D012408:Rubber